In a significant legal victory, the Bombay High Court ruled in favor of Sun Pharma, which has marketed its acidity medication, Pantocid, since 1998. The court's decision came after Sun Pharma raised concerns about Zawadi Healthcare's similar product name, Pantozed, arguing that the similarity could lead to dangerous confusion among healthcare providers and patients. The court's order currently restrains Zawadi from using the name, underlining the importance of distinct branding in the pharmaceutical industry.

Pantocid, a proton pump inhibitor (PPI), is designed to reduce stomach acid production, effectively treating conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and esophagitis. PPIs are typically taken 30 to 60 minutes before meals for optimal effectiveness. While generally well-tolerated, long-term use of PPIs may lead to side effects, including headaches, gastrointestinal issues, and potential risks of bone fractures and kidney problems. Patients are advised to consult their healthcare providers for personalized treatment plans and regular monitoring.